CN110615843B - 一种包含第三信号受体的嵌合抗原受体及其应用 - Google Patents

一种包含第三信号受体的嵌合抗原受体及其应用 Download PDF

Info

Publication number
CN110615843B
CN110615843B CN201810636414.1A CN201810636414A CN110615843B CN 110615843 B CN110615843 B CN 110615843B CN 201810636414 A CN201810636414 A CN 201810636414A CN 110615843 B CN110615843 B CN 110615843B
Authority
CN
China
Prior art keywords
car
pro
ser
cells
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810636414.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110615843A (zh
Inventor
杨选明
傅阳心
汪鑫
叶圣勤
李民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Longyao Biotechnology Co ltd
Original Assignee
Shanghai Longyao Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201810636414.1A priority Critical patent/CN110615843B/zh
Application filed by Shanghai Longyao Biotechnology Co ltd filed Critical Shanghai Longyao Biotechnology Co ltd
Priority to JP2020571580A priority patent/JP7433656B2/ja
Priority to PCT/CN2019/077923 priority patent/WO2019242339A1/zh
Priority to EP19823459.3A priority patent/EP3812401A4/en
Priority to KR1020217001094A priority patent/KR102853978B1/ko
Priority to CN201980041282.0A priority patent/CN112673025B/zh
Priority to CN202210196195.6A priority patent/CN114516922A/zh
Publication of CN110615843A publication Critical patent/CN110615843A/zh
Priority to US17/127,283 priority patent/US11524034B2/en
Priority to US18/047,750 priority patent/US20230134345A1/en
Application granted granted Critical
Publication of CN110615843B publication Critical patent/CN110615843B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810636414.1A 2018-06-20 2018-06-20 一种包含第三信号受体的嵌合抗原受体及其应用 Active CN110615843B (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201810636414.1A CN110615843B (zh) 2018-06-20 2018-06-20 一种包含第三信号受体的嵌合抗原受体及其应用
PCT/CN2019/077923 WO2019242339A1 (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
EP19823459.3A EP3812401A4 (en) 2018-06-20 2019-03-13 CHIMERIC ANTIGEN RECEPTOR WITH A THIRD SIGNAL RECEPTOR AND USE THEREOF
KR1020217001094A KR102853978B1 (ko) 2018-06-20 2019-03-13 제3 신호 수용체를 포함하는 키메릭 항원 수용체 및 이의 용도
JP2020571580A JP7433656B2 (ja) 2018-06-20 2019-03-13 第３シグナル受容体を含むキメラ抗原受容体およびその使用
CN201980041282.0A CN112673025B (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
CN202210196195.6A CN114516922A (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
US17/127,283 US11524034B2 (en) 2018-06-20 2020-12-18 Chimeric antigen receptor comprising third signal receptor and use thereof
US18/047,750 US20230134345A1 (en) 2018-06-20 2022-10-19 Chimeric antigen receptor comprising third signal receptor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810636414.1A CN110615843B (zh) 2018-06-20 2018-06-20 一种包含第三信号受体的嵌合抗原受体及其应用

Publications (2)

Publication Number Publication Date
CN110615843A CN110615843A (zh) 2019-12-27
CN110615843B true CN110615843B (zh) 2023-05-09

Family

ID=68920806

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810636414.1A Active CN110615843B (zh) 2018-06-20 2018-06-20 一种包含第三信号受体的嵌合抗原受体及其应用
CN202210196195.6A Pending CN114516922A (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
CN201980041282.0A Active CN112673025B (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210196195.6A Pending CN114516922A (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用
CN201980041282.0A Active CN112673025B (zh) 2018-06-20 2019-03-13 一种包含第三信号受体的嵌合抗原受体及其应用

Country Status (6)

Country Link
US (1) US11524034B2 (https=)
EP (1) EP3812401A4 (https=)
JP (1) JP7433656B2 (https=)
KR (1) KR102853978B1 (https=)
CN (3) CN110615843B (https=)
WO (1) WO2019242339A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
CN111518219B (zh) * 2020-05-08 2021-06-22 浙江大学 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用
CN112062864A (zh) * 2020-09-18 2020-12-11 樊克兴 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
CN114853900A (zh) * 2021-02-03 2022-08-05 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
EP4402160A4 (en) * 2021-09-17 2025-11-19 Univ Pennsylvania CHIMERIC ANTIGENIC RECEPTORS COMPRISING AN INTERLEUKIN-9 RECEPTOR SIGNALING DOMAIN
AU2022348588A1 (en) 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
KR20250112314A (ko) * 2022-01-10 2025-07-23 페노믹 에이아이 항-콜라겐 삼중 나선 반복 함유 1(cthrc1) 항체 및 이를 사용하는 방법
CN120225568A (zh) * 2022-12-27 2025-06-27 广州瑞风生物科技有限公司 一种融合蛋白及其应用
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
CN117402231B (zh) * 2023-12-14 2024-04-09 南方医科大学南方医院 一种自发传递il-21信号的受体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
CN107245106A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
WO2017184901A1 (en) * 2016-04-20 2017-10-26 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
CN107384870A (zh) * 2017-07-31 2017-11-24 时力生物科技（北京）有限公司 一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832569A1 (en) * 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX370148B (es) * 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN106279434B (zh) * 2014-02-24 2020-07-03 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
WO2016127257A1 (en) * 2015-02-12 2016-08-18 University Health Network Chimeric antigen receptors
WO2016134284A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
IL315940A (en) * 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
CN105949317B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN106397608A (zh) * 2016-10-19 2017-02-15 中国医学科学院血液病医院（血液学研究所） Cd20特异性嵌合抗原受体及其应用
MA46862A (fr) 2016-11-17 2019-09-25 Bluebird Bio Inc Convertisseur de signaux tgf béta
WO2018103734A1 (zh) * 2016-12-09 2018-06-14 北京中捭生物科技有限公司 嵌合抗原受体及其用途和制备方法
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
WO2017184901A1 (en) * 2016-04-20 2017-10-26 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
CN107245106A (zh) * 2017-07-18 2017-10-13 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107384870A (zh) * 2017-07-31 2017-11-24 时力生物科技（北京）有限公司 一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
嵌合抗原受体技术免疫治疗血液系统恶性肿瘤的研究进展;徐晓军等;《中国实验血液学杂志》;20130420(第02期);521-525 *

Also Published As

Publication number Publication date
CN114516922A (zh) 2022-05-20
CN110615843A (zh) 2019-12-27
CN112673025A (zh) 2021-04-16
KR102853978B1 (ko) 2025-09-04
EP3812401A1 (en) 2021-04-28
EP3812401A4 (en) 2022-04-20
JP7433656B2 (ja) 2024-02-20
WO2019242339A1 (zh) 2019-12-26
CN112673025B (zh) 2022-04-01
KR20210023991A (ko) 2021-03-04
US11524034B2 (en) 2022-12-13
US20210169933A1 (en) 2021-06-10
JP2021529176A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
CN110615843B (zh) 一种包含第三信号受体的嵌合抗原受体及其应用
KR20200023165A (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
CN111944062B (zh) 一种识别Fc片段的嵌合抗原受体及其应用
US20230134345A1 (en) Chimeric antigen receptor comprising third signal receptor and use thereof
CN110204619B (zh) 包含FcγRⅠ的嵌合抗原受体及其应用
CN109321530B (zh) 一种安全型嵌合抗原受体t细胞及其用途
CN116041546A (zh) 嵌合抗原受体、分离的核酸、重组载体、car-t细胞及其应用
JP2023522112A (ja) 汎用型ヒト化ｃａｒ１９－ｄｎｔ細胞を製造する技術およびその使用
US11590168B2 (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
CN110616188B (zh) 一种通用型car-t细胞及其制备方法和应用
CN114853893A (zh) 一种靶向gpc3嵌合抗原受体t细胞及其应用
HK40066387A (zh) 一种包含第三信号受体的嵌合抗原受体及其应用
CN116444669B (zh) 靶向bcma car-t细胞人源化抗体
US20230277666A1 (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
HK40074947A (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
HK40042771B (en) Chimeric antigen receptor comprising third signal receptor and use thereof
HK40042771A (en) Chimeric antigen receptor comprising third signal receptor and use thereof
WO2026020799A1 (zh) 靶向b7-h3的抗体、嵌合抗原受体及其应用
HK40042772B (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
HK40042772A (en) Chimeric antigen receptor comprising co-stimulatory receptor and application thereof
HK40077704A (en) Targeted gpc3 chimeric antigen receptor t cell and application thereof
CN120137048A (zh) 一种靶向gpc3的嵌合抗原受体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant